Boris Deutschmann / Source: Mainstay Medical Holdings

Boris Deutschmann, the new country manager for Germany at Dubin, Ireland-based Mainstay Medical Holdings, brings 15 years’ of sales experience in the pharmaceutical and medical device industries, with a focus on pain therapies.

Deutschmann has 10 years’ of experience in neuromodulation and worked in the neuromodulation division of St. Jude Medical (now Abbott) and Nevro Germany. While at Nevro, Deutschmann established the therapy and patient concepts and put together a successful team. He was also credited with increasing business for Nevro to a market share of 30% for RC-IPGS and establishing the HF10 Therapy in Germany. Deutschmann’s background also includes experience as a territory sales manager at Stryker Instruments.

Mainstay has undergone a significant expansion recently and CEO Jason Hannon explained to OTW that the company’s lead product, ReActiv8, is an important innovation in neuromodulation. Specifically, says Hannon, ReActive8 is a compelling therapy for patients suffering from chronic back pain. Mr. Deutschmann, as well as the other new hires, bring, “incredible leadership and experience to help build our commercial capabilities, expand in our existing markets, and launch in the U.S.”

“Each of them is experienced in bringing disruptive new technologies to the market and will help us deliver ReActiv8 to patients suffering from mechanical chronic low back pain and the physicians treating this condition. Collectively they complement the existing strong leadership we already have and will leverage the deep history of clinical and scientific leadership we’ve developed.”

Boris Deutschmann told OTW, “Germany is our initial commercial market and we’ve demonstrated the ability to implement ReActiv8 in real world settings. Now I look forward to changing the lives of many more patients as we expand to all regions in the country.”

“We have established strong relationships with implanting physicians in Germany already, and Boris’ extensive knowledge of the neuromodulation industry in Germany bodes well for our continued expansion in the country,” stated Jason Hannon to OTW.

Leave a comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.